Chlamydia Antibiotics

Treatment for Chlamydial Infections

Chlamydial infections are commonly treated with erythromycin and tetracycline and clinical resistance has not caused problem with these drugs. These are Chlamydia antibiotics used for treatment of chlamydial infections. The antibiotic list has information about chlamydial infections.  The effectiveness of macrolides like erythromycin or azalides like azithromycin is due to their intermolecular concentrations especially in macrophages. These Chlamydia antibiotics can work very effectively. The distribution of macrolides is even in cell cytosol and lysosomes/phagosomes while azalides can concentrate in phagosomes. The location of the tetracycline is poorly defined in the cell. There is slow entrance of amino-glycosides (gentamicin) or Beta-lactam antibiotics (cephalosporins and penicillin) due to which they are poorly or moderately active against chlamydiae.

The similar antibiotic sensitivity is similar in intracellular bacteria like Rickettsia, Chlamydia or Lawsonia. Antibiotic resistance is noted for Chlamydia antibiotics like C. trachomatis but it is still disputed. Its resistance information can be obtained from antibiotic list which is 64mg.ml of tetracycline from France. Multidrug resistance is shown in C. rachomatis to drugs like azithromycin, doxycycline and ofloxacin at concentrations beyond 4 µg per ml. further description of this Chlamydia antibiotic is available in the antibiotic list. It was found that the bacteria residing in other cells permanently may not be able to acquire antibiotic resistance genes. The intracellular pathogens like C. trachomatis and Coxiella burnettii carry plasmids with the help of which antibiotic resistance genes in the antibiotic list can be produced.

Generally, the different Chlamydia antibiotic with antibiotic resistance genes is not available to the chlamydiae but it can easily gain ADP/ATP translocases from the plants showing that there is feasible transfer of the foreign genes thus acting like Chlamydia antibiotic. There can be reduced viability in intermolecular bacteria having antibiotic list in genes and it is also indicated in unconfirmed reports of tetracycline in the C. trachomatis.  There is significant metabolic energy is required for the development of the macrolide or tetracycline resistance in the extracellular bacteria by the active efflux. There will be no availability of the energy for obligate the intracellular bacteria. 

The stepwise gaining of antibiotic resistance by the minor mutations in DNA gyrase or RNA polymerase can be achieved easily by stepwise passage in the cell culture thus making it Chlamydia antibiotic. The resistance of the C. trachomatis L2 to different fluoroquinolones can be increased up to 1000 fold by mutation. But the resistance of the C. pneumoniae to fluoroquinolones cannot be increased through serial passage. The Chlamydia antibiotic effectiveness for reducing chlamydial infections in uncertain and basically depends on metabolic activity. Antibiotic list gives more information. Presently resistance main therapeutic antibiotics for treatment of acute chlamydial infections are not considered to be a major problem.